Evaluation of a Clinically Relevant Drug–Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity

Abstract

Purpose: The combination therapy of rosuvastatin (RSV) and the platelet inhibitor clopidogrel (CP) is widely accepted in the management of cardiovascular diseases. The objective of the present study was to identify the mechanism of RSV–CP DDI and evaluate the risk of hepatotoxicity associated with the concomitant use of CP.Methods: We first studied the effect of CP and its major circulating metabolite, carboxylic acid metabolite (CPC), on RSV transport by overexpressing cells and membrane vesicles. Second, we investigated whether a rat model could replicate this DDI and then be used to conduct mechanistic studies and assess the risk of hepatotoxicity. Then, cytotoxicity assay in hepatocytes, biochemical examination, and histopathology were performed to measure the magnitude of liver injury in the presence and absence of DDI.Results: CP inhibited OATP1B1-mediated transport of RSV with an IC50 value of 27.39 μM. CP and CPC inhibited BCRP-mediated RSV transport with IC50 values of <0.001 and 5.96 μM, respectively. The CP cocktail (0.001 μM CP plus 2 μM CPC) significantly inhibited BCRP-mediated transport of RSV by 26.28%. Multiple p.o. doses of CP significantly increased intravenous RSV plasma AUC0-infinity by 76.29% and decreased intravenous RSV CL by 42.62%. Similarly, multiple p.o. doses of CP significantly increased p.o. RSV plasma AUC0-infinity by 87.48% and decreased p.o. RSV CL by 43.27%. CP had no effect on cell viability, while RSV exhibited dose-dependent cytotoxicity after 96 h incubation. Co-incubation of 100 μM CP and RSV for 96 h significantly increased intracellular concentrations and cell-to-medium concentration ratios of RSV and reduced hepatocyte viability. Histological evaluation of liver specimens showed patterns of drug-induced liver injury. Cholestasis was found in rats in the presence of DDI.Conclusion: CP is not a clinically relevant inhibitor for OATP1B1 and OATP1B3. The primary mechanism of RSV–CP DDI can be attributed to the inhibition of intestinal BCRP by CP combined with the inhibition of hepatic BCRP by CPC. The latter is likely to be more clinically relevant and be a contributing factor for increased hepatotoxicity in the presence of DDI.

Potential drug-drug interactions in drug therapy for older adults with chronic coronary syndrome at hospital discharge: A real-world study

“…Meanwhile, abnormal liver function could be found in chronic heart failure ( Tavazzi et al, 2008 ). Inhibition of intestinal breast cancer resistance protein (BCRP) transporters by clopidogrel is likely to be a contributor of hepatotoxicity ( Ning et al, 2021 ). Once daily clopidogrel is advised to be taken either in the morning or evening, while rosuvastatin in the evening.…”

Interplay Between Drug-Induced Liver Injury and Gut Microbiota: A Comprehensive Overview

“…As of now, there is inadequate research to suggest that the combination of antibiotics and chemicals may result in potential drug–drug interactions and influence the development of drug-induced liver injury. 90 , 91 Yoo et al 92 proposed that when patients taking lovastatin undergo antibiotic therapy, there may be undesirable pharmacokinetic effects owing to the inhibition of gut microbiota. Inadequate control of plasma cholesterol levels has implications for the development of hepatic steatosis.…”

Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis

“…To date, there are not enough studies showing that the combination of antibiotics and chemical agents might lead to potential DDIs and impact the development of DILI (100,101). Yoo et al (102) indicated that antibiotic treatment of patients taking lovastatin might lead to adverse pharmacokinetic effects by suppressing GM.…”